Publication
HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen
dc.contributor.author | Cavaco-Silva, J. | |
dc.contributor.author | Abecasis, A. | |
dc.contributor.author | Miranda, A. | |
dc.contributor.author | Poças, J. | |
dc.contributor.author | Narciso, J. | |
dc.contributor.author | Águas, M. | |
dc.contributor.author | Maltez, F. | |
dc.contributor.author | Almeida, I. | |
dc.contributor.author | Germano, I. | |
dc.contributor.author | Diniz, A. | |
dc.contributor.author | Gonçalves, M. | |
dc.contributor.author | Gomes, P. | |
dc.contributor.author | Cunha, C. | |
dc.contributor.author | Camacho, R. | |
dc.date.accessioned | 2015-10-27T11:43:07Z | |
dc.date.available | 2015-10-27T11:43:07Z | |
dc.date.issued | 2014 | |
dc.description.abstract | To characterize the HIV-2 integrase gene polymorphisms and the pathways to resistance of HIV-2 patients failing a raltegravir-containing regimen, we studied 63 integrase strand transfer inhibitors (INSTI)-naïve patients, and 10 heavily pretreated patients exhibiting virological failure while receiving a salvage raltegravir-containing regimen. All patients were infected by HIV-2 group A. 61.4% of the integrase residues were conserved, including the catalytic motif residues. No INSTI-major resistance mutations were detected in the virus population from naïve patients, but two amino acids that are secondary resistance mutations to INSTIs in HIV-1 were observed. The 10 raltegravir-experienced patients exhibited resistance mutations via three main genetic pathways: N155H, Q148R, and eventually E92Q - T97A. The 155 pathway was preferentially used (7/10 patients). Other mutations associated to raltegravir resistance in HIV-1 were also observed in our HIV-2 population (V151I and D232N), along with several novel mutations previously unreported. Data retrieved from this study should help build a more robust HIV-2-specific algorithm for the genotypic interpretation of raltegravir resistance, and contribute to improve the clinical monitoring of HIV-2-infected patients. | pt_PT |
dc.description.sponsorship | This work was funded by a research grant from Merck & Co., Inc., Whitehouse Station, N.J., USA, and by the European Commission's Seventh Framework Programme (FP7/2007–2013) under the project “Collaborative HIV and Anti-HIV Drug Resistance Network” (CHAIN, grant 223131). J.C.-S. was supported by Fundação para a Ciência e Tecnologia (FCT) with a PhD grant no. SFRH/BD/61141/2009. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | pt_PT |
dc.identifier | 10.1371/journal.pone.0092747 | |
dc.identifier.citation | PLoS One. 2014;9(3):e92747 | pt_PT |
dc.identifier.doi | 10.1371/journal.pone.0092747 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | http://hdl.handle.net/10400.16/1872 | |
dc.language.iso | eng | pt_PT |
dc.peerreviewed | yes | pt_PT |
dc.publisher | Public Library of Science | pt_PT |
dc.relation.publisherversion | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092747 | pt_PT |
dc.title | HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen | pt_PT |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.citation.conferencePlace | United States of America | pt_PT |
oaire.citation.title | PloS one | pt_PT |
oaire.citation.volume | 9(3) | pt_PT |
rcaap.rights | openAccess | pt_PT |
rcaap.type | article | pt_PT |